Home » Topics » Regulatory » EMA

EMA
RSS

EMA grants PRIME designation for asunercept as treatment of glioblastoma

May 30, 2017

Myrcludex B granted EMA PRIME eligibility

May 26, 2017

EMA awards orphan drug designation to Actinium's Actimab-A

May 25, 2017

EMA committee recommends orphan drug designation for MK-0677

May 25, 2017

FDA and EMA accept submissions for UX-003 for mucopolysaccharidosis VII

May 24, 2017

EMA grants orphan drug designation to avacopan for C3 glomerulopathy

May 24, 2017

EMA committee recommends approval of Oxervate for neurotrophic keratitis

May 23, 2017

EMA committee gives positive opinion to brodalumab for plaque psoriasis

May 23, 2017

Cariprazine granted positive opinion in Europe for the treatment of schizophrenia

May 23, 2017

Cardioxane receives positive CHMP opinion in Europe

May 22, 2017

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...